vatalanib has been researched along with Edema in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akritopoulou-Zanze, I; Albert, DH; Arnold, LD; Ashworth, KL; Bouska, JJ; Bousquet, PF; Cunha, GA; Davidsen, SK; Diaz, GJ; Dinges, J; Djuric, SW; Gasiecki, AF; Gintant, GA; Gracias, VJ; Harris, CM; Houseman, KA; Hutchins, CW; Johnson, EF; Li, H; Marcotte, PA; Martin, RL; Michaelides, MR; Nyein, M; Sowin, TJ; Su, Z; Tapang, PH; Xia, Z; Zhang, HQ | 1 |
1 other study(ies) available for vatalanib and Edema
| Article | Year |
|---|---|
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Topics: Alkynes; Animals; Antineoplastic Agents; Binding, Competitive; Cell Line; Edema; ERG1 Potassium Channel; Estradiol; Ether-A-Go-Go Potassium Channels; Female; Humans; Indenes; Mice; Mice, Inbred BALB C; Models, Molecular; Patch-Clamp Techniques; Protein Binding; Pyrazoles; Radioligand Assay; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Uterine Diseases; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |